Whitnell & Co. Grows Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Whitnell & Co. increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 33.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 19,865 shares of the company’s stock after buying an additional 5,000 shares during the quarter. Whitnell & Co.’s holdings in Merck & Co., Inc. were worth $1,672,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Titan Capital Management LLC CA bought a new position in Merck & Co., Inc. in the 2nd quarter worth about $25,000. LFA Lugano Financial Advisors SA lifted its holdings in shares of Merck & Co., Inc. by 250.0% during the 2nd quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock worth $26,000 after acquiring an additional 225 shares during the period. JJJ Advisors Inc. bought a new position in shares of Merck & Co., Inc. during the 2nd quarter worth about $27,000. Cumberland Partners Ltd bought a new position in shares of Merck & Co., Inc. during the 2nd quarter worth about $40,000. Finally, Fusion Family Wealth LLC lifted its holdings in shares of Merck & Co., Inc. by 268.2% during the 2nd quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock worth $41,000 after acquiring an additional 354 shares during the period. 74.95% of the stock is currently owned by hedge funds and other institutional investors.

MRK stock traded up $0.71 during trading on Friday, hitting $83.59. 6,053,527 shares of the stock traded hands, compared to its average volume of 10,105,755. Merck & Co., Inc. has a one year low of $70.89 and a one year high of $87.35. The stock has a market cap of $212.31 billion, a price-to-earnings ratio of 19.26, a P/E/G ratio of 1.80 and a beta of 0.54. The company has a 50 day simple moving average of $84.01 and a 200 day simple moving average of $82.77. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a net margin of 20.26% and a return on equity of 47.94%. The firm had revenue of $12.40 billion during the quarter, compared to the consensus estimate of $11.59 billion. During the same period last year, the firm posted $1.19 EPS. The firm’s quarterly revenue was up 14.9% on a year-over-year basis. As a group, analysts predict that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on MRK shares. Bank of America started coverage on shares of Merck & Co., Inc. in a report on Wednesday, October 16th. They set a “neutral” rating and a $90.00 price objective for the company. Svb Leerink started coverage on shares of Merck & Co., Inc. in a report on Friday, August 16th. They set an “outperform” rating and a $103.00 price objective for the company. Credit Suisse Group reaffirmed a “buy” rating and set a $95.00 price objective on shares of Merck & Co., Inc. in a report on Wednesday, August 7th. JPMorgan Chase & Co. set a $96.00 price objective on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, October 10th. Finally, Leerink Swann started coverage on shares of Merck & Co., Inc. in a report on Thursday, August 15th. They set an “outperform” rating and a $103.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the stock. Merck & Co., Inc. has a consensus rating of “Buy” and a consensus price target of $95.13.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: Inverted Yield Curve

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.